Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
- PMID: 9753709
- DOI: 10.1056/NEJM199810013391402
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
Abstract
Background: Severe osteogenesis imperfecta is a disorder characterized by osteopenia, frequent fractures, progressive deformity, loss of mobility, and chronic bone pain. There is no effective therapy for the disorder. We assessed the effects of treatment with a bisphosphonate on bone resorption.
Methods: In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6.8+/-1.1 mg per kilogram of body weight per year) at 4-to-6-month intervals for 1.3 to 5.0 years. Clinical status, biochemical characteristics reflecting bone turnover, the bone mineral density of the lumbar spine, and radiologic changes were assessed regularly during treatment.
Results: Administration of pamidronate resulted in sustained reductions in serum alkaline phosphatase concentrations and in the urinary excretion of calcium and type I collagen N-telopeptide. There was a mean annualized increase of 41.9+/-29.0 percent in bone mineral density, and the deviation of bone mineral density from normal, as indicated by the z score, improved from -5.3+/-1.2 to -3.4+/-1.5. The cortical width of the metacarpals increased by 27+/-20.2 percent per year. The increases in the size of the vertebral bodies suggested that new bone had formed. The mean incidence of radiologically confirmed fractures decreased by 1.7 per year (P<0.001). Treatment with pamidronate did not alter the rate of fracture healing, the growth rate, or the appearance of the growth plates. Mobility and ambulation improved in 16 children and remained unchanged in the other 14. All the children reported substantial relief of chronic pain and fatigue.
Conclusions: In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density.
Comment in
-
Osteogenesis imperfecta--managing brittle bones.N Engl J Med. 1998 Oct 1;339(14):986-7. doi: 10.1056/NEJM199810013391408. N Engl J Med. 1998. PMID: 9753715 No abstract available.
Similar articles
-
Cyclic pamidronate therapy in children with osteogenesis imperfecta.J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):73-80. doi: 10.1515/jpem.2010.23.1-2.73. J Pediatr Endocrinol Metab. 2010. PMID: 20432809 Clinical Trial.
-
Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.Bone. 2007 Mar;40(3):638-44. doi: 10.1016/j.bone.2006.10.010. Epub 2006 Nov 28. Bone. 2007. PMID: 17127117 Clinical Trial.
-
Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.J Pediatr Endocrinol Metab. 2008 Jan;21(1):63-72. doi: 10.1515/jpem.2008.21.1.63. J Pediatr Endocrinol Metab. 2008. PMID: 18404974 Clinical Trial.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2014 Jul 23;(7):CD005088. doi: 10.1002/14651858.CD005088.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Oct 19;10:CD005088. doi: 10.1002/14651858.CD005088.pub4. PMID: 25054949 Updated. Review.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article. Review.
Cited by
-
Schnurri-3 inhibition rescues skeletal fragility and vascular skeletal stem cell niche pathology in the OIM model of osteogenesis imperfecta.Bone Res. 2024 Aug 26;12(1):46. doi: 10.1038/s41413-024-00349-1. Bone Res. 2024. PMID: 39183236 Free PMC article.
-
Analyses of Osteogenesis Imperfecta in South Korea Using the Nationwide Health Insurance Service Claim Data: A Propensity Score-Matched Study.Calcif Tissue Int. 2024 Aug 16. doi: 10.1007/s00223-024-01274-5. Online ahead of print. Calcif Tissue Int. 2024. PMID: 39150494 Review.
-
Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta.Osteoporos Int. 2024 Jul;35(7):1303-1304. doi: 10.1007/s00198-024-07089-2. Epub 2024 May 8. Osteoporos Int. 2024. PMID: 38717498 No abstract available.
-
Optimising Health-Related Quality of Life in Children With Osteogenesis Imperfecta.Calcif Tissue Int. 2024 May 2. doi: 10.1007/s00223-024-01205-4. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38695871 Review.
-
Home care needs assessment among caregivers of children and adolescents with osteogenesis imperfecta: a cross-sectional study.BMC Prim Care. 2024 Apr 19;25(1):119. doi: 10.1186/s12875-024-02367-8. BMC Prim Care. 2024. PMID: 38641795 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical